the regimen A is not so different as the preparation used in the index colonoscopy (except for bisacodyl) . The rate of patients assuming the regimen A that reach an adequate preparation could be thus theoretically due to bisacodyl per se and the fact that patients are included in a study and the adjunctive effect of the regimen B could be also better evaluated in its nature.
REVIEWER
Franco Radaelli Valduce Hospital, Como<br>Italy Norgine: advisory board REVIEW RETURNED 24-Feb-2019
GENERAL COMMENTS
The ideal bowel preparation for colonoscopy in patients with poor bowel cleansing at a previous colonoscopy is a grey area of colonoscopy where the evidence is still lacking. Thus and the Authors are to be congratulated for this project.
Major comments:
1. There is now great evidence that the regimen of bowel preparation is the main determinant of the quality of bowel preparation, and is much more important than the cleansing agent.Then, I believe that it should have been more reasonable to include in this study, testing two reinforced split regimens of highvolume bowel prep, only patients who had previously failed a standard split regimen (either high-or low-volume). Otherwise, it is difficult to determine which are the real benefits of the reinforced bowel preparation (i.e., the difference could be related to the split regimen rather than to the preparation itself).
2. In the study by Ibanez, 3L PEG + bisacodyl in split regimen allowed to achieve an adequate bowel prep in about 90% of subjects. In the sample size of the study, the Authors set a baseline adequate bowel prep of 70% with regimen A, This is not clear to me, as this regimen should be theoretically more effective than the regimen used by Ibanez. Besides, is the study designed as superiority study? Please clarify An interesting protocol which deals with a daily problem when performing colonoscopy: which kind of preparation for those patients who result not adequately prepared? Some studies managed the issue but data are scarce and of low quality.
VERSION 1 -AUTHOR RESPONSE
The present protocol has the typical design of studies dealing with colon cleansing: two study preparations are compared in a prospective, single blind fashion. Critical in this context is, however, how patients with not adequate preparation are included in the study.
Authors decided to define as inadequate that preparation that does not allow to visualize lesion > 5mm in size. I have, however, some concerns regarding the issue.
First of all, it is likely to be very difficult to objectively evaluate whether preparation is accurate or not. How do endoscopist evaluate whether a 5 mm polyp is visible or not according to the preparations? As stated by the authors endoscopists performing index colonoscopy are not study investigators and are likely to be not familiar with a definition which is not used in clinical practice.
The second point is that the BBPS is used in the study to evaluate the quality of preparation; we could theoretically have the paradoxical situation of a patient adequately prepared by one of the two study preparations which was erroneously judged to be non adequately prepared at the basal endoscopy. I can understand the reason of choosing such a not restrictive definition of failed preparation with the need of aiding subjects recruitment. The inclusion criteria represent, however, a critical issue: the erroneous evaluation of quality of cleansing at index endoscopy may negatively impact on the quality of the study results. Index endoscopy should be performed by trained endoscopists who should have a high rate of agreement regarding the definition of adequate and not adequate preparation.
A further reason of using the BBPS as inclusion criteria would be to have a further aid in evaluating the real benefit of the two study regimens in cleansing the colon: from a theoretical point of view the regimen A is not so different as the preparation used in the index colonoscopy (except for bisacodyl) . The rate of patients assuming the regimen A that reach an adequate preparation could be thus theoretically due to bisacodyl per se and the fact that patients are included in a study and the adjunctive effect of the regimen B could be also better evaluated in its nature.
We thank Dr. Manes for raising this important point. Our study group did thoroughly consider this issue at study inception and during the planning phase. Unfortunately, there are many definitions of inadequate bowel preparation in the literature. We opted for the most universal clinical definition available (ie. one that is not based on a specific bowel preparation scale), that being inability to exclude polyps <5 mm in size, in keeping with endorsement from the US Multi-Society Task Force on Colorectal Cancer since 2002. Using this definition, colonoscopies with inadequate bowel preparation should be repeated in <1 year (USMSTF update on bowel prep in 2014). As such, this definition captures the two most important aspects that define inadequate bowel preparation: inability to exclude polyps and need to repeat the colonoscopy. We humbly disagree with the reviewer's concern that the "endoscopists performing index colonoscopy are not study investigators and are likely to be not familiar with a definition which is not used in clinical practice" as this definition has been available since 2002 and used in multiple clinical reviews and societal guidelines since then (please see updated references in manuscript for examples). Furthermore, the basis of using a 5 mm cut-off and the need to shorten the colonoscopy interval formed the basis to define inadequate bowel preparation for the two most validated bowel preparation scales: the BBPS and the Ottawa score (please see updated references in manuscript for examples).
The other advantage of using a more pragmatic and clinical definition of inadequate bowel prep (ie. the USMSTF definition) is increased generalizability of our findings. As an example, if we instead used BBPS <6 as an inclusion criteria for B-CLEAN(R), our findings would only be of use to physicians who use the Boston score. In its current form, our results are generalizable to any physician who agrees that a colonoscopy where bowel preparation could not exclude polyps <5 mm in size is inadequate and as a result, the colonoscopy should be repeated. In our humble opinion, this makes for a more robust and useful study.
Lastly, to address the concern of the reviewer, we will record the BBPS of the index colonoscopy, when available, as a surrogate marker of how 'dirty' colons were in the study cohort and report on it.
These clarifications and changes have been added to the methods and outcome section of the manuscript, pages 6, 7, 10. The ideal bowel preparation for colonoscopy in patients with poor bowel cleansing at a previous colonoscopy is a grey area of colonoscopy where the evidence is still lacking. Thus and the Authors are to be congratulated for this project.
1. There is now great evidence that the regimen of bowel preparation is the main determinant of the quality of bowel preparation, and is much more important than the cleansing agent.Then, I believe that it should have been more reasonable to include in this study, testing two reinforced split regimens of high-volume bowel prep, only patients who had previously failed a standard split regimen (either high-or low-volume). Otherwise, it is difficult to determine which are the real benefits of the reinforced bowel preparation (i.e., the difference could be related to the split regimen rather than to the preparation itself).
We agree wholeheartedly that split dose bowel preparation is the regimen of choice for modern day colonoscopy and members of our group have published a definitive systematic review on the topic (Gastroenterology 2015; 149:79-88) . At our centres, split dose bowel preparation is already the preferred regimen and anecdotally, 90% of colonoscopies performed at our centres are split dose. However, in reality, day before bowel preparations are still approved by regulators around the world, including Health Canada and the FDA, used by a minority of physicians globally, and as such, we felt that including an exclusion criteria for 'Index colonoscopy performed not using split dose bowel preparation' would be overly restrictive and reduce the generalizability of our results. Instead, to address the reviewer's concern, we will track whether split dose bowel preparation was used at the index colonoscopy to ensure that improved bowel preparation with either Regimen A or B is not due solely to use of split dose in the trial protocol. This has been added to page 10. Overall, we expect that the overwhelming majority of patients in the trial will have failed split dose bowel preparation given the high uptake of split dose bowel prep already used at our centres.
2. In the study by Ibanez, 3L PEG + bisacodyl in split regimen allowed to achieve an adequate bowel prep in about 90% of subjects. In the sample size of the study, the Authors set a baseline adequate bowel prep of 70% with regimen A, This is not clear to me, as this regimen should be theoretically more effective than the regimen used by Ibanez. Besides, is the study designed as superiority study? Please clarify
We reduced the expected adequacy rate from 90% to 70% due to several concerns regarding how the index colonoscopy bowel preparation was performed in 2009. First, 94% of bowel prep at the index colonoscopy was low volume NaP. Second, only 63% of bowel prep was given split dose. As such, given the initial bowel prep was mostly low volume and non-split dose, we felt the patients in their cohort failed less effective index bowel preparation than patients in our study, who would have failed modern day mostly split dose bowel prep. Accordingly, if our patients were 'transported back in time' to undergo Ibanez's study protocol, we expect that less than 90% would achieve adequate bowel preparation during their second colonoscopy (ie. since our patients would have failed more effective index bowel prep than the original patients in 2009). To address the reviewer's concern, we added clarifying statements on page 13 justifying this.
VERSION 2 -REVIEW

REVIEWER
Gianpiero Manes ASST Rhodense, Italy REVIEW RETURNED 29-Apr-2019
GENERAL COMMENTS
In the present form, modified according to the referees' suggestion, the paper is suitable for acceptance
REVIEWER
Franco Radaelli
Valduce Hospital, Como, Italy Norgine: advisory board REVIEW RETURNED 25-Apr-2019
GENERAL COMMENTS
The Authors clearly addressed my concerns
